Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss

Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.While the headlines point to a new trial result that failed to meet expectations, the technical analysis reveals a deeper, more concerning picture of the stock’s momentum.Read News Details: Novo Nordisk’s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges Chart created using Benzinga ProNVO Stock Has Bearish Signals Across The BoardNVO's charts are fi ...